RAPID IMPROVEMENT IN SMELL
Seen as early as
(results are descriptive, definitive conclusions cannot be made as this was a post hoc analysis; data prior to Week 24 were not multiplicity controlled)2,a,b

aLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.12, -0.02).1,3

bWeek 24 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -0.98 (95% CI: -1.15, -0.81) (-1.21 from a baseline score of 2.77 vs -0.23 from a baseline score of 2.72, respectively).4

Loss of Smell (LoS) score (range 0-3); reduced score indicates improvement.5

SUSTAINED IMPROVEMENT
IN UPSIT SCORE THROUGH WEEK 524
SINUS-52 (other secondary endpoint)

Analysis of change at Week 52 was not multiplicity controlled; result is descriptive.

  • Week 24 (SINUS-52): 72% improvement in UPSIT score with DUPIXENT vs 6% worsening with placebo4,c

cWeek 24 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): 10.77 (95% CI: 8.98, 12.56) (9.96 from a baseline score of 13.46 vs -0.81 from a baseline score of 13.78, respectively).4

dWeek 52 in SINUS-52 (other secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): 10.30 (95% CI: 8.50, 12.10) (9.53 from a baseline score of 13.46 vs -0.77 from a baseline score of 13.78, respectively).4


University of Pennsylvania Smell Identification Test (UPSIT) score (range 0-40): higher score indicates improvement.

CI, confidence interval; INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks.

Back to efficacy and safety overview
See nasal congestion score

Explore the Safety Data and Study Designs

View Safety Data
SEE THE FULL STUDY DESIGNS

Dosage and
Administration

See the recommended dosing and administration options for patients on DUPIXENT.

Explore ADMINISTRATION Options